We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Gas Analyzers for POC Validated

By LabMedica International staff writers
Posted on 15 Jan 2018
Several aspects of pH and blood gas analysis are unique in laboratory analysis, and furthermore, no other test results have such a great and immediate impact on patient care. More...
In addition, it is now possible to carry out further vital biological assays on the same sample.

These results provide an overall picture of the patient's state of health, which is especially important for patients admitted to adult and neonatal resuscitation wards (scalp pH), or in emergency medicine. Blood gas analyzers are often integrated into point-of-care testing and this has been evaluated.

Clinical biochemists at the Clermont-Ferrand Teaching Hospital (Clermont-Ferrand, France) installed and assessed 12 GEM PREMIER 4000 analyzers for pH, pCO2, pO2, Na+, K+, Cl-, Ca2+, lactate, hemoglobin (Hb) and oxyhemoglobin (O2Hb). These instruments were distributed across 11 care sites in the hospital. Comparisons between GEM analyzers were performed on 30 samples and between GEM analyzers and the central laboratory for Na+, K+, Cl-, Ca2+ and hemoglobin on 30 to 50 samples. The GEM analyzers were compared with the automated analyzers of the central laboratory. Na+, K+, Cl- and lactate were assayed on a Vista-type analyzer. Ca2+ was assayed on a Siemens RAPIDPoint500 analyzer, and Hb was assayed on an XN analyzer.

The scientists obtained the results for the determination of [H+], pCO2, Na+, Cl-, K+, Ca2+, lactate and O2Hb that all complied with French Society of Clinical Biology (SFBC) recommendations, with corresponding coefficient of variation (CV) values below 1.5%, 3.8%, 0.8%, 1.2%, 1.2%, 1.2%, 3.8% and 3.8% respectively. These tests were carried out over the measurement ranges 6.80–7.58 for pH (100–22 nmol/L H+), 26–150 mmHg for pCO2, 33–203 mmHg for pO2, 125–163 mmol/L for Na+, 86–136 mmol/L for Cl-, 2.4–6.7 mmol/L for K+, 0.25–1.51 mmol/L for Ca2+, 0.8–19 mmol/L for lactate, 6.0–20.7 g/dL for Hb and 37.2–98.4% for O2Hb.

The authors concluded that their results met standard requirements and the 12 analyzers were assessed as suitable for point-of-care testing in services of academic medical centers, as exemplified at Clermont-Ferrand hospital. The study was published on December 13, 2017, in the journal Practical Laboratory Medicine.

Related Links:
Clermont-Ferrand Teaching Hospital



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The study identified a distinct immune signature associated with treatment-resistant myasthenia gravis (Dodd, Katherine C. et al., Med (2026). DOI: 10.1016/j.medj.2025.100987)

Immune Signature Identified in Treatment-Resistant Myasthenia Gravis

Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.